Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve implantation for severe symptomatic aortic valve stenosis

• Verfasst von: Werner, Nicolas [VerfasserIn]
• Verfasst von: Katus, Hugo [VerfasserIn]
• Titel: Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve implantation for severe symptomatic aortic valve stenosis
• Titelzusatz: One-year results from the German Aortic Valve Registry
• Verf.angabe: Nicolas Werner, Ralf Zahn, Andreas Beckmann, Timm Bauer, Sabine Bleiziffer, Christian W. Hamm, Raffi Berkeredjian, Alexander Berkowitsch, Friedrich W. Mohr, Sandra Landwehr, Hugo A. Katus, Wolfgang Harringer, Stephan Ensminger, Christian Frerker, Helge Möllmann, Thomas Walther, Steffen Schneider, Rüdiger Lange
• E-Jahr: 2018
• Jahr: December 4, 2018
• Umfang: 13 S.
• Fussnoten: Gesehen am 12.03.2020
• Titel Quelle: Enthalten in: Circulation
• Ort Quelle: Philadelphia, Pa. : Lippincott, Williams & Wilkins, 1950
• Jahr Quelle: 2018
• Band/Heft Quelle: 138(2018), 23, Seite 2611-2623
• ISSN Quelle: 1524-4539
• DOI: doi:10.1161/CIRCULATIONAHA.117.033048
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1692369245

Abstract

Background: Transcatheter aortic valve replacement (TAVR) is increasingly being used for treatment of severe aortic valve stenosis in patients at intermediate risk for surgical aortic valve replacement (SAVR). Currently, real-world data comparing indications and clinical outcomes of patients at intermediate surgical risk undergoing isolated TAVR with those undergoing SAVR are scarce. Methods: We compared clinical characteristics and outcomes of patients with intermediate surgical risk (Society of Thoracic Surgeons score 4%-8%) who underwent isolated TAVR or conventional SAVR within the prospective, all-comers German Aortic Valve Registry. Results: A total of 7613 patients at intermediate surgical risk underwent isolated TAVR (n=6469) or SAVR (n=1144) at 92 sites in Germany between 2012 and 2014. Patients treated by TAVR were significantly older (82.5±5.0 versus 76.6±6.7 years, P<0.001) and had higher risk scores (logistic EuroSCORE [European System for Cardiac Operative Risk Evaluation]: 21.2±12.3% versus 14.2±9.5%, P<0.001; Society of Thoracic Surgeons score: 5.6±1.1 versus 5.2±1.0, P<0.001). Multivariable analyses revealed that advanced age, coronary artery disease, New York Heart Association class III/IV, pulmonary hypertension, prior cardiac decompensation, elective procedure, arterial occlusive disease, no diabetes mellitus, and a smaller aortic valve area were associated with performing TAVR instead of SAVR (all P<0.001). Unadjusted in-hospital mortality rates were equal for TAVR and SAVR (3.6% versus 3.6%, P=0.976), whereas unadjusted 1-year mortality was significantly higher in patients after TAVR (17.5% versus 10.8%, P<0.001). After propensity score matching, the difference in 1-year mortality between patients with TAVR and SAVR was no longer significant (17.1% versus 15.7%, P=0.59).Conclusions:Patients at intermediate risk undergoing TAVR differ significantly from those treated with SAVR with regard to age and baseline characteristics. Isolated TAVR and SAVR were associated with an in-hospital mortality rate of 3.6%. In the propensity score analysis, there was no significant difference in 1-year mortality between patients with TAVR and SAVR.